Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye injection could stop damaging blood vessels in Herpes-Related blindness

NCT ID NCT07329686

Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether injecting anti-VEGF medication directly into the cornea can safely reduce abnormal blood vessel growth caused by herpes simplex keratitis. One hundred adults will receive either the injection plus antiviral eye drops or standard antiviral drops alone. Researchers will measure changes in blood vessel area, vision, and eye clarity over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
anti-VEGF medication
What this could lead to
If successful, this could offer a new, targeted treatment to reduce abnormal blood vessels in the cornea and improve vision for people with herpes-related eye disease.
What could go wrong
This is an early Phase 1/2 trial with only 100 participants, so results are preliminary. The injection procedure itself carries risks like infection or corneal damage, and the treatment may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis: Patients who meet the diagnostic criteria for Herpes Simplex Virus (HSV) keratitis with neovascularization. * Age: Adults aged 18 years or older. * Previous Treatment: Patients who have not undergone other anti-VEGF treatments or corneal surgeries. * Informed Consent: Patients who are capable of understanding and signing an informed consent form, agreeing to participate in the entire study process and to follow the study's follow-up schedule and treatment plan. * Other: Additional criteria as deemed necessary by the investigator. Exclusion Criteria: * Risk of Corneal Perforation: Patients at risk of corneal perforation. * Severe Ocular Surface Dryness: Patients with severe dry eye syndrome. * Systemic Diseases: Patients with systemic diseases that may affect the nervous or immune systems, such as diabetes, rheumatoid arthritis, autoimmune diseases, etc. * Recent Use of Systemic Immunosuppressants: Patients who have recently used systemic immunosuppressive agents. * Poor Compliance: Patients who are unable to follow up on time or adhere to the treatment plan. * Pregnancy or Lactation: Pregnant or nursing women, as their physiological state may affect study outcomes. * Allergy History: Patients with a history of allergies to the study medication or related components. * Other Reasons: Patients deemed by the investigator to have other reasons making them unsuitable for participation in the trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Corneal neovascularization are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

corneal neovascularization herpes simplex virus keratitis Keratitis, Herpetic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Corneal neovascularization Herpes simplex keratitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • 1 Xihu Avenue, Shangcheng District,Hangzhou, Zhejiang,China,Hangzhou, Zhejiang Completed

    RECRUITING

    Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.